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Abstract
Contribution to epileptic encephalopathy (EE) of mutations in CACNA2D2, encoding a2d-2 subunit of Voltage Dependent
Calcium Channels, is unclear. To date only one CACNA2D2 mutation altering channel functionality has been identified in a
single family. In the same family, a rare CELSR3 polymorphism also segregated with disease. Involvement of CACNA2D2 in EE
is therefore not confirmed, while that of CELSR3 is questionable. In a patient with epilepsy, dyskinesia, cerebellar atrophy,
psychomotor delay and dysmorphic features, offspring to consanguineous parents, we performed whole exome
sequencing (WES) for homozygosity mapping and mutation detection. WES identified extended autozygosity on
chromosome 3, containing two novel homozygous candidate mutations: c.1295delA (p.Asn432fs) in CACNA2D2 and
c.G6407A (p.Gly2136Asp) in CELSR3. Gene prioritization pointed to CACNA2D2 as the most prominent candidate gene. The
WES finding in CACNA2D2 resulted to be statistically significant (p = 0.032), unlike that in CELSR3. CACNA2D2 homozygous
c.1295delA essentially abolished a2d-2 expression. In summary, we identified a novel null CACNA2D2mutation associated to
a clinical phenotype strikingly similar to the Cacna2d2 null mouse model. Molecular and statistical analyses together argued
in favor of a causal contribution of CACNA2D2 mutations to EE, while suggested that finding in CELSR3, although potentially
damaging, is likely incidental.
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Introduction
Epileptic Encephalopathies (EEs) are severe brain disorders in
which the seizures and the epileptic activity itself may cause severe
psychomotor impairment. EEs may arise from the neonatal to the
early infantile period as recurrent, prolonged or drug resistant
seizures, resulting in devastating permanent global developmental
delay with brain atrophy. Occasionally, EEs can be associated to
brain lesions or malformations of cortical development [1]. EEs
are genetically heterogeneous. Numerous genes, all involved in
diverse primary developmental processes of the brain, have been
already identified and their number and that of the associated
clinical spectrum is expanding continuously [1]. Among these the
so-called ‘‘channelopathies’’, originating from defects in genes
coding for neuronal ion channels, play a prominent role in
monogenic epilepsies, among which EEs [2].
Mutations in CACNA1A (MIM 601011), [3] encoding the
transmembrane pore-forming subunit CaV2.1 of Voltage Depen-
dent Calcium Channels (VDCCs), [4] have been associated to the
peculiar phenotypic combination of absence epilepsy and cerebel-
lar ataxia. Auxiliary regulatory subunits a2d, b and c associate
with the pore forming a1 subunit and modulate its function [5,6].
Several mouse models, all characterized by homozygous mutations
in one of the genes encoding VDCC subunits, share similar
phenotypes including cerebellar ataxia, paroxysmal dyskinesia and
seizures similar to those of absence epilepsy as well as other forms
of generalized epilepsy. Among these the ducky mutant mice, which
carry null alleles in Cacna2d2, represent a model for absence
epilepsy characterized by behavioral arrest synchronous with
spike-wave discharges and cerebellar ataxia [7,8]. a2d is encoded
by a single gene and is post-translationally modified to form two
proteins, d and a2: the d piece, a single-pass trans-membrane
portion, anchors the a2 protein to the membrane [9]. It acts
mainly by enhancing the trafficking or reducing the turnover of
the channel complex in the plasma membrane [8,10]. The a2d-2
subunit is involved in the composition of a variety of different
VDCCs, but it contributes mainly to Cav2.1/b4 (P-type current)
in central synapses [9].
Recently, a homozygous CACNA2D2 (Calcium Channel,
Voltage Dependent, a2d subunit 2; MIM 607082) mutation was
identified in a family with 3 siblings, offspring to consanguineous
parents, who presented with early-onset epileptic encephalopathy
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e82154
and global developmental delay. This mutation, a probably
pathogenic missense p.Leu1040Pro substitution, affected a highly
conserved residue and was shown to cause dysfunction of a2d-2,
resulting in reduced current density and slow inactivation in
neuronal calcium channels (Table 1) [11]. Another possibly
detrimental rare p.Met2630Ile polymorphism (rs149614835) in
CELSR3 (Cadherin EGF LAG 7-pass G-type receptor 3; MIM
604264) (Table 1) segregated with the disease phenotype in the
same family. These findings supported the hypothesis that
defective a2d-2 may underlie the epileptic phenotype. However,
this observation was not confirmed in independent patients and a
role in disease pathogenesis of the concomitant CELSR3 variant
could not be ruled out [11]. Here we report on abolished
expression of a2d-2 in a patient, offspring to consanguineous
parents characterized by the association of epilepsy with also
absence seizures, dyskinetic movements and cerebellar atrophy, a




The proband is an Italian 9-years-old boy, offspring to first
cousins, with an older and healthy sister. We followed this patient
since the age of 2 years. He was born at 40 weeks after an
uneventful pregnancy and delivery. During the first months of life,
the child presented hypertonus and eye rolling movements.
Afterwards, a severe delay of psychomotor development became
apparent, characterized by legs hypertonia, axial hypotonia,
dyskinetic movements and myoclonic jerks of the arms and the
head, no eye contact, and uncoordinated eye movements. The first
epileptic seizure occurred at 5 months without fever, characterized
by salivation, loss of contact and clonic jerks on the left side of the
Table 1. Features of the CACNA2D2 and CELSR3 mutations.
Present work Edvardson et al., 2013 (11)
Gene CACNA2D2 CELSR3 CACNA2D2 CELSR3
Frequency Novel Novel Novel ,0.001 (rs149614835)
Genomic position chr3:50416390 chr3:48687978 chr3:50402595 chr3:48682550
cDNA change c.1295delA c.341G.A c.3119A.G c.7890G.A
Protein change p.N432fs* p.G114D p.L1040P p.M2630I
GERP score1 – 5.07 4.76 5.24
Pathogenicity prediction – Tolerated (SIFT) Damaging (MT)
Probably Damaging (Polyphen2)
Damaging (SIFT, MT) Damaging (SIFT, MT)
1GERP (Genomic Evolutionary Rate Profiling) is a measure of the nucleotide evolutionary conservation. It ranges from212.3 to 6.17, with 6.17 being the most conserved
[30].
doi:10.1371/journal.pone.0082154.t001
Figure 1. Instrumental findings in the proband. Left panel: EEG recording during wakefulness showing generalized spike-wave complex at 4 Hz
lasting thirteen seconds with absence, eye up deviation and eyelid myoclonia. Right panel: Sagittal T1 MRI showing prominent cerebellar atrophy.
doi:10.1371/journal.pone.0082154.g001
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body. The first seizure lasted 20 minutes and the interictal EEG
showed slow waves on the left occipital regions. Over time, several
seizure types occurred, characterized by: a) left eye and head
deviation with clonic jerks on the left side of the body; b)
generalized hypertonia, loss of contact, uncoordinated movements
of eye and limbs, cyanosis, and facial and arms twitching; or c) loss
of contact, generalized hypotonia and clonic jerks, and tachycardia
or bradychardia. Occasionally, at the end of the ictal event,
dyskinetic (particularly choreiform) movements of the limbs
appeared, without recovery of consciousness. The seizures, with
or without fever, could be prolonged (20–30 minutes) and were
frequently followed by sleep. Between seizures, the child always
showed head tonic extension, erratic limb movements and tremor.
The interictal EEG showed multifocal spikes over the right centro-
temporal and the left parieto-occipital regions.
At three years of age, absences with eye up deviation and eyelid
myoclonus appeared (Figure 1). The other seizure types persisted,
although reduced in frequency. Seizures were resistant to many
drugs (phenobarbital, benzodiazepine, valproic acid, levetirace-
tam, lamotrigine); absences frequency was improved by ethosux-
imide. The EEG recordings showed slowing background activity,
multifocal, diffuse paroxysmal abnormalities, and a transitory
photosensitivity.
Clinical examination showed dysmorphisms(bilateral epican-
thus, arched palate, pronounced Cupid’s bow, narrow naris,
clinodactyly of the IV and V fingers) and head circumferences
between 3 and 10 percentiles. Neurologic examination showed
oculo-motor apraxia, strabismus, nystagmus, axial and leg
hypertonia, head tonic extension, erratic limb movements, tremor
and brisk symmetric reflexes. At the most recent follow-up, it was
substantially unchanged, and the child had two types of seizures:
very brief absences during wakefulness and tonic-clonic seizures
during sleep, which were prevalent on the left side. Laboratory
investigations showed hyperglycaemia, and glicosuria. Genetic
(high resolution karyotype, analysis for Angelman and Dravet
syndromes) and metabolic investigations (urine organic acids,
amino acids, isoelectric focusing of transferrins), including those
for mitochondrial pathology, were all negative. The ECG and
cardiac examination were normal. Brain MRI was remarkable for
cerebellar atrophy (Figure 1).
Whole Exome Sequencing for Variant Detection and
Autozygosity Mapping
Whole exome DNA from patient’s whole blood was captured
using the TruSeq exome enrichment kit (Illumina Inc., San Diego,
CA, USA) and sequenced as 100 bp paired-end reads on Illumina
HiSeq2000 platform (Illumina Inc., San Diego, CA, USA).
Generated reads have been deposited in the European
Nucleotide Archive with accession number PRJEB4676 (http://
www.ebi.ac.uk/ena/data/view/PRJEB4676). Reads were
checked with FastQC (http://www.bioinformatics.babraham.ac.
uk/publications.html) and aligned with BWA [12] to the reference
genome hg19. Aligned reads were treated for realignment and
base quality score recalibration with GATK, [13] and for
Figure 2. Genetic mapping and segregation of CACNA2D2 c.C1295delA mutation. Upper panel: barcode plot showing EX-HOM on
chromosome 3. If the SNP is heterozygous, y = 0, if it is homozygous y = 1. Black bars represent regions of mixed heterozygous/homozygous SNPs,
whilst white bars regions of contiguous homozygous SNPs. Different colors reflect the type of mutation: CELSR3 has a missense variant (black),
CACNA2D2 has a loss-of-function variant (red). Lower panel: the CACNA2D2 c.C1295delA mutation segregates with the disease in the nuclear pedigree
(parents are 1st cousins).
doi:10.1371/journal.pone.0082154.g002
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duplicate removal with PicardTools (http://picartools.
sourceforge.net). Alignment statistics were collected by SAMtools
[14] and GATK. Coverage statistics over the targeted regions
were calculated with GATK. Variant calling and filtering by
quality were performed by GATK. Variants passing quality filters
were annotated separately against NCBI RefGene (http://www.
ncbi.nlm.nih.gov) and UCSC KnownGene (http://genome.ucsc.
edu).
WES genotypes of polymorphic sites present in dbSNP135
(http://www.ncbi.nlm.nih.gov/snp/) were retrieved to create a
genetic map consisting of 1673111 sites in the targeted exome, in
order to perform autozygosity mapping in the proband as
described elsewhere [15].
Gene Prioritization
To enhance prioritization of candidate genes harboring novel,
probably detrimental variants detected by WES, we used
Exomiser (http://www.sanger.ac.uk/resources/databases/
exomiser/) [16], an on-line tool that functionally annotates and
prioritizes mutated genes using criteria as variant frequency,
predicted pathogenicity, inheritance pattern and model organism
phenotype data. Scores are based on Mutation Taster [17], SIFT
[18] and Polyphen2 [19] for predicted pathogenicity of mutations
and on Mouse PhenoDigm [20] for phenotypical overlap with the
animal model. We adopted the following criteria: 1) autosomal
recessive model; 2) phenotypic classification according to the HPO
(Human Phenotype Ontology) terms (http://www.human-
phenotype-ontology.org): a) epileptiform EEG discharges, b)
cerebellar atrophy and c) dyskinesia; 3) removal of variants with
allele frequency .1% and predicted as non-pathogenic. To
calculate the probability that a mutation falling in a candidate
gene is truly associated with disease, we used the on-line tool
Exome Power Calculator [21] (exomepower.ssg.uab.edu/) to
obtain p-values as measure of statistical significance of the WES
findings. Exome Power Calculator provides a simple statistical
framework to guide quantitative data analysis by setting the
following parameters: 1) Ps, sequence sensitivity: the probability
that a variant in the targeted regions is correctly called; 2) m, per
individual number of candidate variants; 3) w, relative gene length
(ratio of the protein length to the genomic average); 4) n, sample
size (number of unrelated patients sequenced); 5) M, total number
of genes in the mutational target; 6) a, significance level of the test
after Bonferroni correction; 7) o, observed value for the statistic; 8)
T, underlying genetic model (dominant/recessive/additive). We
assumed Ps = 1 (100% sensitivity), a = 0.05, M=20653 [22], the
underlying genetic model Tr. From the Uniprot database (http://
www.uniprot.org/), we retrieved the protein product length of
CACNA2D2 (1150 amino acids) and CELSR3 (3312 amino acids).
Based on the average genomic protein length of 447 amino acids
[23], we calculated w= 2 for CACNA2D2 (1150/447) and w=7 for
CELSR3 (3312/447). We calculated m as the mean individual
number of ‘‘candidate variants’’ from our internal exome database
(n = 50 exomes). Since we found a loss-of-function mutation in
CACNA2D2, we calculated m either including all the coding
nonsynonymous, canonical splice-site and coding small indels
mutations with population frequency ,1% (mall), or applying a
more stringent filter by selecting only loss-of-function (nonsense
Figure 3. CACNA2D2 mRNA and protein expression. Left panel: the mRNA content of the proband was evaluated by Real Time-PCR and
normalized on that of control individuals (n = 4). CACNA2D2 mRNA resulted strongly reduced in the proband (II:1, 18%), father (I:1, 28%) and mother
(I:2, 54%) compared to controls (Anova test, p,0.001). Data are shown as mean6 standard error of three independent experiments. Right panel: the
protein content was evaluated by Western blot and normalized on that of control individuals (n = 3), using GAPDH as reference protein and loading
control. Graph shows data obtained by densitometric analysis. The proband (II:1) showed a 3% of protein expression compared to controls (Anova on
Ranks test, p = 0.034), whereas both parents (I:1 and I:2) had ,50% of expression. Data are expressed as mean6 standard error of three independent
experiments. Representative western blot is shown.
doi:10.1371/journal.pone.0082154.g003
Table 2. Calculation of the level of statistical significance of
WES findings in candidate genes.
m (n6 variants) CACNA2D2 (w=2) CELSR3 (w=7)
mall (584) 0,999 1,000
mlof (19) 0,032 0,109
doi:10.1371/journal.pone.0082154.t002
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mutations and coding small frameshift indels with population
frequency ,1%) mutations (mlof). mall resulted to be 584, while
mlof 19.
Muscle Biopsy
Muscle biopsy of the proband was performed by open surgery
after informed consent. Four normal muscle biopsies were used as
controls. Muscle specimens were frozen in cooled isopentane and
stored in liquid nitrogen. Standard staining (H&E, Gomori
modified trichrome, Oil Red O, PAS) and histoenzymatic
activities (SDH, COX, NADH, ATPase pH 9.4 and 4.3) were
performed following standard protocol [24].
Expression Analysis
Total RNA was extracted from 150 muscle slices (20 mm thick)
by TriPure isolation reagent (Roche) and 1 mg of total RNA was
reverse transcribed using the Transcriptor First Strand cDNA
Synthesis Kit (Roche). CACNA2D2 expression was evaluated by
real time-PCR, using the Universal Probe Library (Roche) system.
The analysis has been conducted in triplicate and the CACNA2D2
concentration has been calculated through a standard curve by
absolute quantification and normalized on TUBB expression.
Total proteins were extracted from 50 muscle slices (20 mm
thick) adding 100 ml of RIPA buffer (50 mM Tris–Cl pH 7.6,
150 mM NaCl, 1% NP-40, 1% NaDOC, 0.1% SDS, 5 mM
EDTA) and 100 ml/ml of protease inhibitor cocktail (Roche). The
lysates were sonicated and centrifuged at 10000 g and the protein
content of the supernatant was determined according to Bradford
[25]. Proteins (100 mg) were separated by 8% SDS–PAGE and
transferred onto a nitrocellulose membrane (Bio-Rad). Monoclo-
nal primary antibodies specific for CACNA2D2 65–162 aa (Abnova
M12 clone 4E3, 1:100) and GAPDH (Sigma Aldrich, G8795 clone
71.1, 1:20000) were visualized using horseradish peroxidase-
conjugated secondary antibodies (Invitrogen, 1:2000). Signals were
detected using ImmobilonTM Western peroxidase substrate
(Merck-Millipore). Densitometry was performed with a LAS-
3000 Imaging System (FUJIFILM) and Image J software [26]. The
analysis was conducted in triplicate and CACNA2D2 protein
expression was normalized on GAPDH expression in each sample.
Anova test was used to evidence significant differences between
groups.
This study was approved by the local ethics committee of
Polyclinic Sant’Orsola-Malpighi, Bologna, Italy. We obtained
written informed consent from both the parents. All clinical
investigation was conducted according to the principles expressed
in the declaration of Helsinki.
Results
WES yielded 88.24X mean coverage over the targeted exome
with the 80.2% of the exomic positions covered .20X. Due to the
recent parental relatedness, we selected the 13 regions .5
megabases (Table S1) as the ones with the highest probability
to be autozygous and therefore to carry the causative variant
among all the EX-HOM regions identified in the proband. We
selected candidate genes as those harboring variants with reported
frequency ,1% or no reported frequency, and predicted to alter
the protein product (nonsynonymous SNVs, canonical splice-site
mutations and InDels). We used Exomiser to prioritize variants
according to mutation type, predicted pathogenicity score and
association to human or animal model phenotypes. The top-
scored variant (Table S2) was the c.1295delA (p.Asn432fs) frame-
shift deletion in CACNA2D2 (Table 1). This 1-nucleotide deletion
received among the highest scores for both pathogenicity (0.95)
and phenotype (0.88), the former due to deleteriousness of the
frameshift mutation, the latter to the striking similarity between
the clinical picture and the Cacna2d2-null mouse models pheno-
types. This variant lied within the longest proband’s autozygous
region (Table S1 and Figure 2) and was confirmed by Sanger
Sequencing as homozygous in the proband and as heterozygous in
the healthy sister and in the two parents (Figure 2). The
p.Asn432fs mutation causes truncation in the the a2d-2 protein at
the level of the a2 piece, which is composed by aminoacid residues
from 19 to 1001 [9]. This predicts a protein that lacks anchoring to
the membrane and therefore is unable to assemble with the pore
forming subunit. In the brain, the protein encoded by CACNA2D2,
a2d-2, is mostly abundant in the cerebellum and particularly in
Purkinje cells, [27] consistent with the patient’s cerebellar atrophy.
The muscle biopsy from the proband, histologically characterized
by some variability of fiber size with occasional hypotrophic type
II fibers and signs of mitochondrial subsarcolemmal proliferation
(data not shown), demonstrated that CACNA2D2 expression was
dramatically reduced compared to controls (Figure 3). mRNA
quantification showed a ,80% of reduction of CACNA2D2 gene
expression in the proband compared to control individuals
(p,0.001), whereas the father and the mother showed a reduction
of ,70% and ,50% (p,0.001) respectively (Figure 3, left
panel). Accordingly, the protein in the proband resulted almost
absent (3% of expression, p,0.05), and both the parents presented
,50% of CACNA2D2 protein expression (Figure 3, right
panel).
These findings enforced the hypothesis that dysfunction of a2d-
2 is a cause of EE. However, as in the previous report of a
CACNA2D2 mutation in early onset EE, [11] we noticed the
concomitant occurrence of a CELSR3 variant that segregated with
disease in the family (data not shown). This was a nonsynonymous
c.6407G.A (p.Gly2136Asp) change, highly conserved and pre-
dicted as deleterious by 2/3 predictors (Table 1). This reintro-
duced the question whether CACNA2D2 and CELSR3 mutations
might act together in causing the epileptic phenotype. In order to
evaluate the probability that each of these variants is truly disease-
associated and not an incidental WES finding, we calculated the
level of statistical significance of finding a CACNA2D2 or CELSR3
variant in an individual WES experiment using Exome Power
Calculator. Only the occurrence of a recessive loss-of-function
mutation in CACNA2D2 reached statistical significance (p= 0.032)
(Table 2). Based on molecular and statistical evaluation we
concluded that the loss-of-function variant in CACNA2D2, leading
to abolished expression of the encoded protein, was causative of
EE in the proband while the nonsynonymous change in CELSR3,
although potentially damaging, was likely an incidental finding.
Discussion
Our study strengthens the evidence that CACNA2D2 loss-of-
function mutation causes EE. As highlighted by gene prioritization
using the Exomiser tool, p.Asn432fs in CACNA2D2 emerged as the
most prominent candidate from the WES performed in the
proband. Expression data clearly showed that a2d-2 was virtually
absent in the carrier of the homozygous p.Asn432fs mutation,
involving mutations of regulatory VDCC subunits, so far
extensively studied only in the animal models, in human epilepsy.
The striking similarity between the patient’s and the ducky mouse
model phenotypes strongly implicated CACNA2D2 in the disease
pathogenesis. Mouse and human a2d-2 are 95% identical [7]. In
both mice carrying homozygous ducky alleles (du/du and du2J/
du2J), wild-type Cacna2d2 transcript is not detected in the brain
CACNA2D2 and Epileptic Encephalopathy
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and mutant transcripts would encode proteins that are unlikely
functional.
In the 3 previously reported affected siblings mutated in
CACNA2D2, the p.Leu1040Pro nonsynonymous change was
associated with a clinical picture slightly different from the case
described here: the three affected siblings had earlier onset of
epileptic seizures (20–60 days of age vs. 5 months of the present
case); they displayed atonic, clonic and tonic attacks without
focality rather than partial or absence seizures; they did not show
dysmorphic features; their EEG picture was consistent with a
Lennox-Gastaut syndrome rather than being characterized by
multifocal paroxysmal abnormalities and typical absences as
observed in the present case. Epilepsy with different type of
seizures, including partial, hemiclonic, and typical absence seizures
seems to characterize the disruptive mutation described here. This
suggests that only total loss of functional a2d-2 may induce the
distinctive epileptic features observed in the present case. Only
studies involving larger numbers of patients with CACNA2D2
mutations will provide confirmation of this hypothesis.
The presence of variants in CELSR3 in two unrelated families
with EE and CACNA2D2mutations could in principle be explained
by a joint contribution of these two genes to the EE phenotype.
Although CELSR32/2 mice display gross structural brain
alterations that do not resemble any features of the affected
children in the two families, [28] a role for the CELSR3 mutations
cannot be ruled out. Inactivation of CELSR3 in mice causes
abnormalities in cerebral cortex connectivity [29]. The two
CELSR3 mutations, p.Met2630Ile in the previously reported
family and p.Gly2136Asp in the present one, are rare or novel
nonsynonymous changes affecting highly conserved residues, and
therefore are both variants with a putative detrimental role.
However the present CELSR3 mutation was not predicted as
pathogenic by all the predictors used, unlike the one previously
reported (Table 1) [11]. Therefore, in light of our results clearly
showing the disruptive effect of the p.Asn432fs mutation, we
explored the possibility that the CELSR3 variants were only
incidentally detected in the two families. Focusing on the analysis
of the present single proband alone, we obtained that the detection
of the p.Gly2136 Asp in CELSR3 was not statistically significant.
This is due to the relatively excessive length of its encoded protein
(about 7-fold the genomic average), that inflates the number of
variants that can be randomly drawn from this gene in a WES
setting. Conversely, detection of p.Asn432fs in CACNA2D2, which
encodes a shorter protein (about 2-fold the genomic average)
resulted to be statistically relevant applying a stringent loss-of-
function filtering. CACNA2D2 and CELSR3 are only 1.7 megabases
apart on chromosome 3. It follows that a haplotype harboring a
CACNA2D2 disease-causing mutation can be found to coinciden-
tally carry a CELSR3 rare or novel polymorphism, and that due to
recent parental relatedness both the two variants appear in the
homozygous state. In order to prove with certainty that the
CELSR3 does not contribute to cause the EE pathogenesis, further
patients should be recruited that do show mutations in CACNA2D2
but not in CELSR3. However, it is often difficult to recruit
additional patients or families with an ultra-rare disorder such as
the one affecting the present proband. Here, we demonstrated that
functional and statistical validation together can be valuable
resource to collect evidence of causality or non-causality of reliable
WES variant findings.
In conclusion, our results strengthened the association of
CACNA2D2 mutations to EE. The data we collected suggested
that a2d-2 genotype-phenotype correlation may depend on
different levels of residual a2d-2 activity. Our analyses indicated
that the CELSR3 variants were potentially deleterious but likely
incidental findings, demonstrating that molecular and statistical
reasoning can assist in discriminating the true disease-causing from
the reliable but non causative candidate variants that emerge from
the individual WES data.
Supporting Information
Table S1 Extended autozygous regions identified in the
proband.
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